Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (81-90 of 261) with videos related to

Pageof 27
Sort By:
European Urology Oncology|November 17, 2023
Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based StudyLars Egevad, Chiara Micoli, Hemamali Samaratunga, et al.
Scandinavian Journal of Urology|March 17, 2026
Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based studyPaolo Zaurito, Rolf Gedeborg, Hans Garmo, et al.
Scandinavian Journal of Urology|March 25, 2026
Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy resultsEugenio Ventimiglia, Rolf Gedeborg, Marcus Westerberg, et al.
European Urology Open Science|July 23, 2025
Adaption of the Memorial Sloan Kettering Cancer Center Nomograms for the Prediction of Prostate Cancer-specific Death in Sweden: A Population-based Cohort StudyRenata Zelic, Marcus Westerberg, Pär Stattin, et al.
Journal of Clinical Pathology|March 13, 2025
Time trends in Gleason score distribution among Gleason score 8 and 9-10 cancersLars Egevad, Chiara Micoli, Brett Delahunt, et al.
Acta Oncologica (Stockholm, Sweden)|September 19, 2019
Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based studyMarcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, et al.
BJUI Compass|September 15, 2025
Potential gains from radical treatment of men with prostate cancer according to life expectancySandra Irenaeus, Hans Garmo, Rolf Gedeborg, et al.
European Urology Open Science|May 2, 2022
Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients-A Nationwide Population-based StudyOskar Bergengren, Helena Kaihola, Ann-Charlotte Borgefeldt, et al.
Journal of Clinical Epidemiology|December 20, 2022
Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidenceMarcus Westerberg, Kerri Beckmann, Rolf Gedeborg, et al.
Pathology|February 9, 2025
Gleason scores provide more accurate prognostic information than grade groupsLars Egevad, Chiara Micoli, Brett Delahunt, et al.
Pageof 27

Showing results (81-90 of 261) with videos related to

Sort By:
Pageof 27
European Urology Oncology|November 17, 2023
Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based StudyLars Egevad, Chiara Micoli, Hemamali Samaratunga, et al.
Scandinavian Journal of Urology|March 17, 2026
Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based studyPaolo Zaurito, Rolf Gedeborg, Hans Garmo, et al.
Scandinavian Journal of Urology|March 25, 2026
Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy resultsEugenio Ventimiglia, Rolf Gedeborg, Marcus Westerberg, et al.
European Urology Open Science|July 23, 2025
Adaption of the Memorial Sloan Kettering Cancer Center Nomograms for the Prediction of Prostate Cancer-specific Death in Sweden: A Population-based Cohort StudyRenata Zelic, Marcus Westerberg, Pär Stattin, et al.
Journal of Clinical Pathology|March 13, 2025
Time trends in Gleason score distribution among Gleason score 8 and 9-10 cancersLars Egevad, Chiara Micoli, Brett Delahunt, et al.
Acta Oncologica (Stockholm, Sweden)|September 19, 2019
Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based studyMarcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, et al.
BJUI Compass|September 15, 2025
Potential gains from radical treatment of men with prostate cancer according to life expectancySandra Irenaeus, Hans Garmo, Rolf Gedeborg, et al.
European Urology Open Science|May 2, 2022
Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients-A Nationwide Population-based StudyOskar Bergengren, Helena Kaihola, Ann-Charlotte Borgefeldt, et al.
Journal of Clinical Epidemiology|December 20, 2022
Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidenceMarcus Westerberg, Kerri Beckmann, Rolf Gedeborg, et al.
Pathology|February 9, 2025
Gleason scores provide more accurate prognostic information than grade groupsLars Egevad, Chiara Micoli, Brett Delahunt, et al.
Pageof 27